产品编号:GM-87824AB
产品名称:Anti-TA-MUC1(CD227)-DXD (Dar8)[DS-3939]
目录价:询价

产品编号:GM-87824AB
产品名称:Anti-TA-MUC1(CD227)-DXD (Dar8)[DS-3939]
目录价:询价

GM-87824AB-100 100μg
GM-87824AB-1mg 1mg
Expression System  | CHO  | 
Purity  | > 95% as determined by SDS-PAGE  | 
Aggregation  | < 5% as determined by SEC-HPLC  | 
Drug-to-Antibody Ratio (DAR)  | 8.0  | 
Endotoxin  | <1EU/mg  | 
Sterility  | 0.22 μm Filtered  | 
Target  | CD227  | 
Clone  | DS-3939  | 
Alternative Names  | ADMCKD, ADMCKD1, ADTKD2, CA 15-3, CD227, Ca15-3, EMA, H23AG, KL-6, MAM6, MCD, MCKD, MCKD1, MUC-1, MUC-1/SEC, MUC-1/X/ZD, PEM, PEMT, PUM  | 
Source/Isotype  | Monoclonal Human IgG1, κ  | 
Application  | Positive control of Cytotoxicity Assay  | 
Description  | DS-3939 is an antibody-drug conjugate (ADC) candidate drug developed for targeted cancer therapy. It typically consists of a monoclonal antibody that specifically recognizes tumor-associated antigens, chemically linked to a cytotoxic payload. This type of drug aims to enhance antitumor activity and selectivity by precisely targeting tumor cells via the antibody, thereby reducing damage to normal cells.  | 
Formulation  | 10 mM NaAc-HAc, pH5.0  | 



产品编号:GM-87824AB
产品名称:Anti-TA-MUC1(CD227)-DXD (Dar8)[DS-3939]
目录价:询价

GM-87824AB-100 100μg
GM-87824AB-1mg 1mg
Expression System  | CHO  | 
Purity  | > 95% as determined by SDS-PAGE  | 
Aggregation  | < 5% as determined by SEC-HPLC  | 
Drug-to-Antibody Ratio (DAR)  | 8.0  | 
Endotoxin  | <1EU/mg  | 
Sterility  | 0.22 μm Filtered  | 
Target  | CD227  | 
Clone  | DS-3939  | 
Alternative Names  | ADMCKD, ADMCKD1, ADTKD2, CA 15-3, CD227, Ca15-3, EMA, H23AG, KL-6, MAM6, MCD, MCKD, MCKD1, MUC-1, MUC-1/SEC, MUC-1/X/ZD, PEM, PEMT, PUM  | 
Source/Isotype  | Monoclonal Human IgG1, κ  | 
Application  | Positive control of Cytotoxicity Assay  | 
Description  | DS-3939 is an antibody-drug conjugate (ADC) candidate drug developed for targeted cancer therapy. It typically consists of a monoclonal antibody that specifically recognizes tumor-associated antigens, chemically linked to a cytotoxic payload. This type of drug aims to enhance antitumor activity and selectivity by precisely targeting tumor cells via the antibody, thereby reducing damage to normal cells.  | 
Formulation  | 10 mM NaAc-HAc, pH5.0  | 


